Raphael Pharmaceutical Inc (RAPH)

Raphael Pharmaceutical (OTCQB: $RAPH ) presents live at 11:30 AM ET on Thursday, September 17, 2026, at the Life Sciences Virtual Investor Forum, hosted by Virtual Investor Conferences, where B2i Digital is the Official Marketing Partner. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. See event details and profiles of presenting companies at: https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum Raphael Pharmaceutical is a pharmaceutical research and development company working on the discovery and clinical development of drug therapies based on cannabinoids: • Its most advanced development candidates are novel, patentable formulations designed to treat rheumatoid arthritis, which is the lead candidate, along with chronic lung inflammation and autoimmune disease • The company collaborates with outside research experts and applies rigorous scientific methods and advanced technologies to the development of its cannabinoid-based formulas • The company's stated goal is life-improving drug therapies that are safe and effective, and its formulations are at the development-candidate stage The thirty-minute presentation includes a live question and answer session with management, and replays follow on the B2i Digital and OTC Markets YouTube channels after the event. To register and view the presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5492508/raphael-pharmaceutical-otcqb-raph?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC Presenting company website: https://www.raphaelpharmaceutical.com/ To request a one-on-one meeting with management: https://app.axleaccess.com/public/events/019cf1e8-5723-46bd-8ded-5b7a610d6f8e?token=85aa08be-2ca5-442e-b15f-88291e58a98a B2i Digital, The Capital Markets Matchmaker℠, carries each presenting company's story From Marketing to Meetings℠, across its media network with a combined monthly audience of more than 330 million and its own community of 1.7 million+ investors and market participants. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

$SONA.CSE $RAPH $APTN $ACXP $CYDY Thanks! At first I thought you were spamming lol. How did you know about it? Are you involved and I wonder who is presenting for cydy. I only saw they were a presenting company.

Thursday, September 17: The Life Sciences Virtual Investor Forum, live online, hosted by Virtual Investor Conferences. Oncology. Fibrosis. Drug delivery. Antibiotics. Cannabinoid therapeutics. Respiratory imaging. Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind. A B2i Digital Featured Conference. Event details and profiles of presenting companies: https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum Scheduled to present (subject to change): 11:00 AM ET: Sona Nanotech Inc. (OTCQB: SNANF | CSE: $SONA.CSE ) 11:30 AM ET: Raphael Pharmaceutical (OTCQB: $RAPH ) 2:00 PM ET: Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX) 2:30 PM ET: Adaptin Bio, Inc. (OTCQB: $APTN ) 3:00 PM ET: Acurx Pharmaceuticals, Inc. (Nasdaq: $ACXP) 3:30 PM ET: CytoDyn Inc. (OTCQB: $CYDY ) 4:00 PM ET: 4DMedical Ltd. (OTC: FDMDF | ASX: 4DX) Can't watch live? Replays go up on the B2i Digital and OTC Markets YouTube channels. Register: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC To request one-on-one meetings with management: https://app.axleaccess.com/public/events/019cf1e8-5723-46bd-8ded-5b7a610d6f8e?token=85aa08be-2ca5-442e-b15f-88291e58a98a B2i Digital, The Capital Markets Matchmaker℠, carries each presenting company's story From Marketing to Meetings℠ across its media network with a 330 million+ combined monthly audience and its own community of 1.7 million+ investors and market participants. Virtual Investor Conferences is an OTC Markets Group Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.

$RAPH - Raphael Pharmaceutical Inc. - 10K - Updated Risk Factors RAPH's 2025 10-K Risk Factors highlight reliance on key officers, control by major stockholders, financial instability, regulatory hurdles, competition, and operational risks, including cybersecurity threats and international expansion challenges. #CorporateGovernance #InternationalExpansion #Cybersecurity #RegulatoryChallenges #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/RAPH/10-K/2025-03-31

$WMT $CBDL $RAPH

Yesterday's Recap: $RAPH Clinical Study Results for the Treatment of Rheumatoid Arthritis $CBDL Breakthrough Walmart $WMT Marketplace Approval for Mushroom Supplement

$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of-Concept-Clinical-Study-Results-for-the-Company-s-Cannabinoid-Based-Formula-for-the-Treatment-of-Rheumatoid-Arthritis.html

$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of-Concept-Clinical-Study-Results-for-the-Company-s-Cannabinoid-Based-Formula-for-the-Treatment-of-Rheumatoid-Arthritis.html

$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of-Concept-Clinical-Study-Results-for-the-Company-s-Cannabinoid-Based-Formula-for-the-Treatment-of-Rheumatoid-Arthritis.html